Jérôme Guillemont

6.6k citations

47 papers · 4.6k indexed · 2 hit papers · h-index 21

Co-authors: Koen Andries Anil Koul Nacer Lounis Éric Arnoult Hinrich W. H. Göhlmann Dirk Bald Vincent Jarlier Philip Timmerman
Topics: Cancer therapeutics and mechanisms (13 papers)Tuberculosis Research and Epidemiology (12 papers)HIV/AIDS drug development and treatment (12 papers)
Cited by: Infectious Diseases Molecular Medicine Epidemiology
Journals: Nature Science Journal of Biological Chemistry
Partner nations: France United States Belgium

In The Last Decade

Jérôme Guillemont

44 papers receiving 4.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis

2004 1.6k citations Koen Andries, Peter Verhasselt et al. Science profile →
The challenge of new drug discovery for tuberculosis

2011 831 citations Anil Koul, Éric Arnoult et al. Nature profile →

Peers

Countries citing papers authored by Jérôme Guillemont

Since Specialization

Citations

This map shows the geographic impact of Jérôme Guillemont's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jérôme Guillemont with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jérôme Guillemont more than expected).

Fields of papers citing papers by Jérôme Guillemont

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jérôme Guillemont. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jérôme Guillemont. The network helps show where Jérôme Guillemont may publish in the future.

Co-authorship network of co-authors of Jérôme Guillemont

This figure shows the co-authorship network connecting the top 25 collaborators of Jérôme Guillemont. A scholar is included among the top collaborators of Jérôme Guillemont based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jérôme Guillemont. Jérôme Guillemont is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A new synthetic route towards multifunctionalized cyclic amidrazones for feeding chemical space 2024 ·Organic & Biomolecular Chemistry ·(unknown),(unknown),(unknown),Monique Mathé‐Allainmat,Sandrine Grosse,Jérôme Guillemont,Jacques Lebreton,Arnaud Tessier	0
2	Synthesis of 7’‐Substituted 2’‐O‐4’‐C‐Ethylene Bridged Nucleic Acid (ENA)‐Thymidine Monomers 2023 ·European Journal of Organic Chemistry ·(unknown),(unknown),(unknown),Jérôme Guillemont,Leonid Beigelman,Julien Brioche,Serge R. Piettre	2
3	Use of 3-(Pentafluorosulfanyl)phenol to Access to Advanced Substituted Pentafluorosulfanylphenol/anisole: Application to the Synthesis of 2-(Arylpentafluorosulfanyl)indanedione 2021 ·Letters in Organic Chemistry ·(unknown),(unknown),Laurence Quéguiner,(unknown),Jérôme Guillemont	1
4	Synthesis and evaluation of analogues of the tuberculosis drug bedaquiline containing heterocyclic B-ring units 2017 ·Bioorganic & Medicinal Chemistry Letters ·Peter J. Choi,Hamish S. Sutherland,Amy S.T. Tong,Adrian Blaser,Scott G. Franzblau,Christopher B. Cooper,(unknown),Anna M. Upton,Jérôme Guillemont,(unknown),Laurence Quéguiner,Koen Andries,(unknown),William A. Denny,Brian D. Palmer	48
5	Probing the Interaction of the Diarylquinoline TMC207 with Its Target Mycobacterial ATP Synthase 2011 ·PLoS ONE ·Anna C. Haagsma,(unknown),Anil Koul,Koen Andries,Jérôme Guillemont,Holger Lill,Dirk Bald	103
6	The challenge of new drug discovery for tuberculosisbreakdown → 2011 ·Nature ·Anil Koul,Éric Arnoult,Nacer Lounis,Jérôme Guillemont,Koen Andries	831
7	R207910 (TMC207) : un nouvel antibiotique pour le traitement de la tuberculose 2009 ·Médecine et Maladies Infectieuses ·Nacer Lounis,Jérôme Guillemont,Nicolas Véziris,A. Koul,Vincent Jarlier,Koen Andries	19
8	A novel route to 2,4-dianilino-substituted pyrimidines 2009 ·Tetrahedron Letters ·Ruben G.G. Leenders,Jan Heeres,Jérôme Guillemont,Paul Lewi	3
9	Diarylquinolines Are Bactericidal for Dormant Mycobacteria as a Result of Disturbed ATP Homeostasis 2008 ·Journal of Biological Chemistry ·Anil Koul,Luc Vranckx,Najoua Dendouga,Wendy Balemans,Ilse Van den Wyngaert,Karen Vergauwen,Hinrich W. H. Göhlmann,Rudy Willebrords,Alain Poncelet,Jérôme Guillemont,Dirk Bald,Koen Andries	262
10	Diarylquinolines target subunit c of mycobacterial ATP synthase 2007 ·Nature Chemical Biology ·Anil Koul,Najoua Dendouga,Karen Vergauwen,(unknown),Luc Vranckx,Rudy Willebrords,Zorica Stanojević-Ristić,Holger Lill,Ismet Dorange,Jérôme Guillemont,Dirk Bald,Koen Andries	433
11	A computational model of the inhibition of Mycobacterium tuberculosis ATPase by a new drug candidate R207910 2007 ·Proteins Structure Function and Bioinformatics ·Marc R. de Jonge,(unknown),Jérôme Guillemont,Anil Koul,Koen Andries	93
12	Synthesis of Novel Diarylpyrimidine Analogues of TMC278 and Their Antiviral Activity Against HIV‐1 Wild‐Type and Mutant Strains. 2007 ·ChemInform ·Jérôme Guillemont,(unknown)	1
13	Structure–activity relationship in the 3-iodo-4-phenoxypyridinone (IOPY) series: The nature of the C-3 substituent on anti-HIV activity 2006 ·Bioorganic & Medicinal Chemistry Letters ·(unknown),(unknown),Jérôme Guillemont,Élisabeth Pasquier,(unknown),Koen Andries,Chi Hung Nguyen,David S. Grierson	13
14	Conformational Analysis of R207910, a New Drug Candidate for the Treatment of Tuberculosis, by a Combined NMR and Molecular Modeling Approach 2006 ·Chemical Biology & Drug Design ·(unknown),(unknown),Christophe Meyer,Pascal Bonnet,(unknown),Hassan Oulyadi,Jérôme Guillemont	35
15	Absolute configuration and structural features of R207910, a novel anti-tuberculosis agent 2006 ·Journal of Molecular Structure ·Samuel Petit,Gérard Coquerel,Christophe Meyer,Jérôme Guillemont	13
16	Synthesis of novel diarylpyrimidine analogues of TMC278 and their antiviral activity against HIV-1 wild-type and mutant strains 2006 ·European Journal of Medicinal Chemistry ·Céline Mordant,(unknown),Élisabeth Pasquier,(unknown),Laurence Quéguiner,Chantal Masungi,Anik Peeters,(unknown),(unknown),Kurt Hertogs,Jan Heeres,Paul Lewi,Jérôme Guillemont	60
17	4-Benzyl and 4-Benzoyl-3-dimethylaminopyridin-2(1H)-ones: In Vitro Evaluation of New C-3-Amino-Substituted and C-5,6-Alkyl-Substituted Analogues against Clinically Important HIV Mutant Strains 2005 ·Journal of Medicinal Chemistry ·(unknown),(unknown),Claude Monneret,Émile Bisagni,(unknown),(unknown),Alain Poncelet,(unknown),Jérôme Guillemont,Christophe Meyer,Koen Andries,Rudi Pauwels,Marie‐Pierre de Béthune,D.M. Himmel,Kalyan Das,Eddy Arnold,Chi Hung Nguyen,David S. Grierson	27
18	A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosisbreakdown → 2004 ·Science ·Koen Andries,Peter Verhasselt,Jérôme Guillemont,Hinrich W. H. Göhlmann,Jean‐Marc Neefs,Hans Christian Winkler,Jef Van Gestel,Philip Timmerman,Min Zhu,(unknown),Peter Williams,(unknown),Emma Huitric,Sven Hoffner,Emmanuelle Cambau,C. Truffot-Pernot,Nacer Lounis,Vincent Jarlier	1632
19	4-Benzyl- and 4-Benzoyl-3-dimethylaminopyridin-2(1H)-ones, a New Family of Potent Anti-HIV Agents: Optimization and in Vitro Evaluation against Clinically Important HIV Mutant Strains 2004 ·Journal of Medicinal Chemistry ·(unknown),(unknown),Jérôme Guillemont,(unknown),(unknown),Alain Poncelet,(unknown),Koen Andries,Rudi Pauwels,Marie‐Pierre de Béthune,Claude Monneret,Émile Bisagni,Chi Hung Nguyen,David S. Grierson	17
20	3-Iodo-4-phenoxypyridinones (IOPY's), a new family of highly potent non-nucleoside inhibitors of HIV-1 reverse transcriptase 2003 ·Bioorganic & Medicinal Chemistry Letters ·(unknown),Jérôme Guillemont,Koen Andries,Chi Hung Nguyen,David S. Grierson	29

About Jérôme Guillemont

Jérôme Guillemont is a scholar working on Virology, Infectious Diseases and Molecular Medicine, having authored 47 papers that have together received 4.6k indexed citations. Recurring topics across this work include Cancer therapeutics and mechanisms (13 papers), Tuberculosis Research and Epidemiology (12 papers) and HIV/AIDS drug development and treatment (12 papers). The work is most often cited by research in Infectious Diseases (2.9k citations), Molecular Medicine (539 citations) and Epidemiology (1.6k citations). Jérôme Guillemont has collaborated with scholars based in France, United States and Belgium. Frequent co-authors include Koen Andries, Anil Koul, Nacer Lounis, Éric Arnoult, Hinrich W. H. Göhlmann, Dirk Bald, Vincent Jarlier, Philip Timmerman, Emmanuelle Cambau and Hans Christian Winkler. Their work appears in journals such as Nature, Science and Journal of Biological Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact